Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elad Sharon

Showing results (121-130 of 191) with videos related to

Pageof 20
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 14, 2022
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic LeukemiaAnjali S Advani, Anna Moseley, Kristen M O'Dwyer, et al.
Systematic Reviews|May 8, 2021
Repurposing existing medications for coronavirus disease 2019: protocol for a rapid and living systematic reviewBenjamin P Geisler, Lara Zahabi, Adam Edward Lang, et al.
Cancer Immunology, Immunotherapy : CII|January 18, 2024
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatmentJoanna Baginska, Allison Nau, Ilana Gomez Diaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2021
Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue SarcomasGeraldine O'Sullivan Coyne, Shivaani Kummar, James Hu, et al.
Nature Communications|January 9, 2025
Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trialJyoti Mayadev, Dmitriy Zamarin, Wei Deng, et al.
The Oncologist|June 3, 2026
Assessing Contribution of Effect in Oncology Combination Therapies: Lessons Learned to Inform and Optimize Future Registrational Trial DesignsHillary Andrews, Raja Agnihotram, Gideon Blumenthal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2020
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine TumorsSandip P Patel, Megan Othus, Young Kwang Chae, et al.
JAMA Oncology|June 3, 2019
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 StudyThomas S Uldrick, Priscila H Gonçalves, Maher Abdul-Hay, et al.
Nature|March 19, 2026
Thymic health and immunotherapy outcomes in patients with cancerSimon Bernatz, Vasco Prudente, Suraj Pai, et al.
Blood Advances|February 24, 2026
A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
Pageof 20

Showing results (121-130 of 191) with videos related to

Sort By:
Pageof 20
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 14, 2022
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic LeukemiaAnjali S Advani, Anna Moseley, Kristen M O'Dwyer, et al.
Systematic Reviews|May 8, 2021
Repurposing existing medications for coronavirus disease 2019: protocol for a rapid and living systematic reviewBenjamin P Geisler, Lara Zahabi, Adam Edward Lang, et al.
Cancer Immunology, Immunotherapy : CII|January 18, 2024
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatmentJoanna Baginska, Allison Nau, Ilana Gomez Diaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2021
Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue SarcomasGeraldine O'Sullivan Coyne, Shivaani Kummar, James Hu, et al.
Nature Communications|January 9, 2025
Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trialJyoti Mayadev, Dmitriy Zamarin, Wei Deng, et al.
The Oncologist|June 3, 2026
Assessing Contribution of Effect in Oncology Combination Therapies: Lessons Learned to Inform and Optimize Future Registrational Trial DesignsHillary Andrews, Raja Agnihotram, Gideon Blumenthal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2020
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine TumorsSandip P Patel, Megan Othus, Young Kwang Chae, et al.
JAMA Oncology|June 3, 2019
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 StudyThomas S Uldrick, Priscila H Gonçalves, Maher Abdul-Hay, et al.
Nature|March 19, 2026
Thymic health and immunotherapy outcomes in patients with cancerSimon Bernatz, Vasco Prudente, Suraj Pai, et al.
Blood Advances|February 24, 2026
A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
Pageof 20